奥希替尼 + 巩固放疗：晚期 EGFR 突变 NSCLC II 期研究
类型: II期临床试验 / 系统治疗 + 局部治疗 发表日期: 2025-08-26 入库日期: 2026-05-21 来源: PubMed / EClinicalMedicine 标签: EGFR L858R, 奥希替尼, 巩固放疗, 残留病灶, 局部治疗
Citation
Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial. EClinicalMedicine. 2025. PMID: 41054436. DOI: 10.1016/j.eclinm.2025.103435
Why it matters for mom
This is not exactly her current situation because she has already had prolonged systemic therapy and mixed disease behavior. It is still useful because it supports the broader concept that local control of residual/progressing lesions can be integrated with EGFR inhibition.
Practical takeaways
- Local treatment is not only for symptoms; in selected EGFR-mutant cases it may be part of disease-control strategy.
- It should be discussed with a radiation oncologist who is comfortable with metastatic lung cancer and bone/soft-tissue targets.
- Timing matters: best response, oligoprogression, pain, and biopsy need may point to different decisions.
Questions for doctors
- Are there any residual/progressing sites that would benefit from consolidative or salvage radiation?
- Would radiation interfere with future biopsy or trial eligibility?
- How should systemic therapy be held or continued around radiation?